Nafithromycin, brief Introduction
Nafithromycin, developed with the support of the Biotechnology Industry Research Assistance Council (BIRAC), is India’s first indigenous antibiotic aimed at combating Antimicrobial Resistance (AMR). It is marketed under the trade name “Miqnaf” by Wockhardt and specifically addresses Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria.
Talking about its Efficacy, it’s Ten times more potent than current antibiotics like azithromycin, achieving equivalent outcomes with just a three-day treatment. In case of Safety and Tolerability it Causes minimal gastrointestinal side effects, has no major drug interactions, and maintains consistent efficacy regardless of food intake.
Nafithromycin is the first antibiotic in its class to be developed globally in over three decades. It is specifically designed to target both typical and atypical pathogens, addressing a broad spectrum of infections. Its innovative mechanism effectively overcomes resistance pathways, making it a vital tool in combating multi-drug-resistant pathogens.
Development and it’s costs
The development of Nafithromycin is the result of 14 years of dedicated research and an investment of ₹500 crores. Its clinical trials were conducted across the U.S., Europe, and India, ensuring comprehensive evaluation and validation. The project was supported by BIRAC through the Biotechnology Industry Partnership Program (BIPP), showcasing the power of collaborative innovation in advancing healthcare solutions.
Review by an AMR Expert
We spoke with Prof. Fatima Khan from the Department of Microbiology at Aligarh Muslim University, who praised the launch of India’s first indigenous antibiotic, Nafithromycin, as a remarkable accomplishment.
She explained that, based on available literature this novel lactone ketolide is an effective option against atypical bacteria and drug-resistant pathogens, particularly MRSA and Streptococcus pneumoniae, which are common causes of community-acquired pneumonia (CAP). Its innovative mechanism, including additional ribosomal binding interactions, significantly reduces the likelihood of resistance development, making it a promising addition to the antimicrobial arsenal.
Concerns surrounding the drug
However, she emphasised that it is crucial to acknowledge the limitations also. It exhibits no or limited activity against Gram-negative pathogens like Enterobacterales and Pseudomonas aeruginosa, which are the primary culprits behind many infections in Indian healthcare settings, including bloodstream infections and urinary tract infections. Given this, it may be premature to position Nafithromycin as a comprehensive solution to address drug-resistant pathogens in India.
Talking about Multifaceted Approach
Moreover, while new antibiotics are essential in addressing antimicrobial resistance (AMR), they are not a standalone solution. Tackling AMR requires a multifaceted approach:
- Judicious Use of Antibiotics: Ensuring that antibiotics are prescribed only when necessary and appropriate, in alignment with evidence-based guidelines.
- Infection Control Measures: Strengthening hospital infection control practices, including hand hygiene, sterilization protocols, and isolation of infected patients, to prevent the spread of resistant organisms.
- Antimicrobial Stewardship Programs (AMSPs): Implementing robust AMSPs to monitor and regulate antibiotic usage while promoting education and awareness among healthcare workers.
Further Directions
Nafithromycin is currently awaiting final approval from the Central Drugs Standard Control Organization (CDSCO) for widespread use. Moving forward, there is a pressing need for sustained investment in research and development, enhanced healthcare infrastructure, and strengthened collaboration among government bodies, research institutions, and the pharmaceutical industry to maximize its impact and address the challenges posed by antimicrobial resistance.
The Medical Bulletin
Leave a Reply